Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1438569 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $8.20Day +0.61%1Y −22.1%Off 52W high −26.4%Vol (1Y) 31.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,809 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Days to cover8.2d |
| Top-10 13F concentration75.7% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)€7.21B |
| Earnings (TTM)€156.9M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (EUR). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−11.1% |
| 1Y−22.1% |
| 3Y−22.6% |
| 5Y−44.5% |
| 10Y−43.7% |
| Since incept. (ann.)+2.1% |
Total return through 2026-07-30 · series begins 2011-06-02. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)31.6% |
| Ann. volatility (3Y)51.3% |
| Sharpe (1Y)−0.54 |
| Sharpe (3Y)0.09 |
| Max drawdown (1Y)−34.1% |
| Max drawdown (3Y)−52.7% |
| Beta (3Y vs SPY)0.92 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | 36.3M | $291M | — | +17.4% |
| Capital World Investors | 22.9M | $184M | — | +0.0% |
| Permian Investment Partners, LP | 19.4M | $155M | — | +6.4% |
| Black Creek Investment Management Inc. | 8.4M | $67M | — | −9.4% |
| MILLENNIUM MANAGEMENT LLC | 5.0M | $40M | — | −29.7% |
| BANK OF AMERICA CORP /DE/ | 4.3M | $35M | — | +0.2% |
| JANUS HENDERSON GROUP PLC | 3.3M | $26M | — | −3.8% |
| UBS Group AG | 3.2M | $25M | — | +23.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for GRFS.
